Menopausal hormone therapy and breast cancer: what is the true size of the increased risk?
Michael E. Jones(Institute of Cancer Research), Anthony J. Swerdlow(Institute of Cancer Research), Lauren B. Wright(Institute of Cancer Research), James M. Griffin(Institute of Cancer Research), Alan Ashworth(University of California, San Francisco), Dawn Thomas(Institute of Cancer Research), Karen A. Wright(Public Health England), Minouk J. Schoemaker(Institute of Cancer Research), Jane Hemming(Institute of Cancer Research), Emily McFadden(John Radcliffe Hospital)
Cited by 95
Related Papers
BRCA1 Basal-like Breast Cancers Originate from Luminal Epithelial Progenitors and Not from Basal Stem Cells
|Cell stem cell|2010|814
Genome-wide association study identifies five susceptibility loci for glioma
|Nature Genetics|2009|797
<i>FGFR1</i> Amplification Drives Endocrine Therapy Resistance and Is a Therapeutic Target in Breast Cancer
|Cancer Research|2010|740
Prediction of Breast Cancer Risk Based on Profiling With Common Genetic Variants
|JNCI Journal of the National Cancer Institute|2015|570
Germline mutations in RAD51D confer susceptibility to ovarian cancer
|Nature Genetics|2011|545